Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.

Titel:: Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial.
Dokumenttyp:: Letter; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Autor(en):: Kubasch, A S; Peterlin, P; Cluzeau, T; Götze, K S; Sockel, K; Teipel, R; Jentzsch, M; Attalah, H; Sebert, M; Chermat, F; Gloaguen, S; Puttrich, M; Cross, M; Schneider, M; Kayser, S; Schipp, D; Giagounidis, A; Tirado-Gonzalez, I; Descot, A; van de Loosdrecht, A; Weigert, A; Metzeler, K H; Fenaux, P; Medyouf, H; Platzbecker, U; Ades, L
Zeitschriftentitel:: Leukemia
Jahr:: 2023
Band / Volume:: 37
Heft / Issue:: 11
Seitenangaben Beitrag:: 2309-2313
Volltext / DOI:: doi:10.1038/s41375-023-02029-1
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/37735558
Print-ISSN:: 0887-6924
TUM Einrichtung:: Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann)
BibTeX

Vorkommen: